Plné znění - 19/2025 Sb.

Sdělení Ministerstva zahraničních věcí, kterým se mění a doplňují sdělení Ministerstva zahraničních věcí č. 58/2007 Sb. m. s. a č. 46/2008 Sb. m. s.

19/2025 Sb.
 

Sdělení

INFORMACE

19

SDĚLENÍ

Ministerstva xxxxxxxxxxxx xxxx,

xxxxxx xx xxxx x xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx věcí č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
&xxxx;

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx sděluje, xx xxx 1. xxxxx 2023 bylo generální xxxxxxxxxx XXXXXX xxxxxxxx xxxxxxxxx xxxxxx znění Xxxxxxx X - Xxxxxx xxxxxxxxxx xxxxx x xxxxx xxxxxxx xxx xxx 2024 - Mezinárodní standard Xxxxxxxxxxx úmluvy xxxxx xxxxxxx xx sportu.

S xxxxx xxxxxx Xxxxxxx X xxxxxxxx souhlas Xxxxxxxxx Xxxxx xxxxxxxxx x prezident xxxxxxxxx xxxxxxxx listinu x xxxxxxx změn Přílohy X Xxxxxx xxxxxxxxxx.

Xxxx xxxxx Xxxxxxx I xxxxxxxxx v xxxxxxxx x xxxxxxx x článkem 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2024, xxx Xxxxxx republiku vstoupilo x xxxxxxxx xxx 18. června 2024 x xxxxxxxxx Přílohu X xxx rok 2023, platnou od 1. xxxxx 2023, xxxxx xxxxxxxxx x xxxxxxxx xxx Xxxxxx xxxxxxxxx dne 22. xxxxxx 2023 x xxxx xxxxxxxxx pod č. 32/2023 Sb. m. s.

Xxxxxxxx xxxxx Přílohy X xxx rok 2024 x xxxx xxxxxxx do xxxxxxx xxxxxx xx vyhlašují xxxxxxxx.
&xxxx;

Xxxxxxx:

x x. JUDr. Xxxxxx, Ph.D., LL.M., x. x.

xxxxxx ředitel xxxxx xxxxxx a xxxxxxxxxx
&xxxx;

Xxxxxxx č. 1

Xxxxxxx xxxxxxxxxxx smlouvy xx xxxxxxx xxxxxx

Xxxx

Xxxxxx xxxxxxxxxx xxxxx x xxxxx xxxxxxx xx povinný Xxxxxxxxxxx xxxxxxxx x xxxxx Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxx.

Xxxxxx xx každoročně xxxxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx procesu zprostředkovaném Xxxxxxxx xxxxxxxxxxxxxx agenturou (XXXX). Xxxxxx je xxxxxx xx 1. xxxxx 2024.

Xxxxxxxxx xxxx Xxxxxxx zakázaných látek x xxxxx bude xxxxxxxxx WADA x xxxx xxxxxxxxxx x xxxxxxxxxx x xxxxxxxxxxxxx. X xxxxxxx xxxxxxxxxxx xxxxxxxxxxxxx xxxx anglickým x xxxxxxxxxxxx textem xxxxxxxxx xxxxx v xxxxxxxxxx.

Xxxx xxxx xxxxxxx xxxxxxx xxxxx xxxxxxxxx x xxxxx Seznamu xxxxxxxxxx xxxxx a xxxxx.

Xxxxxxxx Xxx soutěži

Pokud XXXX pro xxxx xxxxx neschválila xxxx xxxxxx, je období Xxx xxxxxxx v xxxxxx xxxxxxx xxxxxxxxxxx xxxxx před xxxxxxx (xx 23:59 xxxxx) x xxx xxxxxxxxxxxxx Xxxxxxx, které xx xx Xxxxxxxxx xxxxxxxxx, xx xx xxxxx Xxxxxxx x xxxxxxx xxxxxx Xxxxxx.

Xxxxxxxx xxxxx

Xx xxxxxxx, že daná xxxxx nebo metoda xx zakázána Xxx xxxxxxx i Xxxx xxxxxx, xxx xx xxxxxxxxxx x Xxxxxx.

Xxxxxxxxxx x Xxxxxxxxxxxx

Xxxxx xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx Xxxxxx „xxx xxxxx xxxxxxxx xxxxxx 10 xxxxx všechny Zakázané xxxxx Xxxxxxxxxxxx xxxxxxx, x výjimkou xxxx xxxxxxxxxx x Xxxxxxx xxxxxxxxxx látek a xxxxx xxxxxxx. Xxxxx Xxxxxxxx xxxxxx nebude Xxxxxxxxxxx xxxxxxx, xxxxx xxxx x Xxxxxxx xxxxxxxxx označena jako Xxxxxxxxxx xxxxxx.“ Xxxxx xxxxxxxxx x xxxxxx „Xxxxxxxxxx xxxxx x Xxxxxxxxxx xxxxxx uvedené x xxxxxx 4.2.2 xx xxxxxx xxx xxxxxx způsobem xxxxxxxxxx xx xxxx xxxxxxxx xxxx xxxx xxxxxxxxxx xxx xxxx xxxxxxxxx xxxxx nebo xxxxxx. Xxx xxxxx o xxxxx x xxxxxx, xxxxx Xxxxxxxxx xxxxxxxxxxxxx xxxx xxxx xxxxxx x xxxxxx xxxxx xxx ke zlepšení xxxxxxxxxxx xxxxxx.“

Xxxxxxxx xxxxx

Xxxxx xxxxxx 4.2.3 Xxxxxx xxxx Xxxxxxxx látky xxxxxxxxxx xxxx xxxxx, xxxxx xxxx jako xxxxxx označeny z xxxxxx jejich xxxxxxx xxxxxxxxxx ve xxxxxxxxxxx xxxx xxxxx xxxxxx. Xxxx Návykové xxxxx xxxx označovány xxxx xxxxx: xxxxxx, diamorfin (xxxxxx), methylendioxymetamfetamin (MDMA/„extáze“), xxxxxxxxxxxxxxxxxxx (THC).

S0 XXXXXXXXXXX XXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Specifické xxxxx.

Xxxxxxxxx xxxxxxxxxxxxxx xxxxx, xx xxxxxx xx xxxxxxxxxx xxxxx x xxxxxxxxxxxxx xxxxxx Xxxxxxx a xxxxx xxxx x xxxxxxxx době xxxxxxxxx xxxxxx xxxxxxx zdravotnickým xxxxxxxxxx orgánem xxx xxxxxxx xxxxxxx u xxxx (xxxx. léčiva x xxxxxxxxxxxxx nebo xxxxxxxxx vývoji xxxx xxxxxxx xxxxx xxx xxxxxxx, syntetické xxxxx, xxxxx xxxxxxxxx pouze xxx xxxxxxxxxxx použití), xx zakázána xxxxx.

Xxxx xxxxx zahrnuje xxxxx xxxxxxx látek, mimo xxxx XXX-157, 2,4-xxxxxxxxxxxx (XXX) a xxxxxxxxxx xxxxxxxxx (např. Xxxxxxxxxxx x Xxxxxxxxxx).

X1 XXXXXXXXXX XXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X MIMO XXXXXX)

Xxxxxxx zakázané xxxxx x této xxxxx xxxx Nespecifické xxxxx.

Xxxxxxxxxx xxxxx xxxx xxxxxxxx.

X1.1. XXXXXXXXXX ANDROGENNÍ XXXXXXXX (XXX)

Xxx xxxxxxxxx xxxxxx, xxxx xxxx včetně:

•	1-androstenediol (5ɑ-xxxxxxx-1-xx-3ß, 17ß-diol)		•	formebolon
•	1-androstenedion (5ɑ-xxxxxxx-1-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxx (17ɑ-xxxxxx [1,2,5]oxadiazolo[3’,4’:2,3]-5ɑ-androstan-17ß-ol)
•	1-androsteron (3ɑ-xxxxxxx-5x-xxxxxxx-1-xx-17-xx)		&xxxx;•	xxxxxxxxx
•	1-xxxxxxxxxxxxxx (3ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-17-xx)		&xxxx;•	xxxxxxxxxx
•	1-xxxxxxxxxxx (17ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-3-xx)		&xxxx;•	xxxxxxxxxx
•	4-xxxxxxxxxxxxxx (xxxxxxx-4-xx-3ß, 17ß-xxxx)		&xxxx;•	xxxxxxxxxxx (17ß-hydroxy-17ɑ-methylandrosta-1,4-dien-3-on)
•	4-hydroxytestosteron(4,17ß-dihydroxyandrost-4-en-3-on)		•	metenolon
•	5-androstenedion (xxxxxxx-5-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxx
•	7ɑ-xxxxxxx-XXXX		&xxxx;•	xxxxxxxxxx (17β-xxxxxxx-2α,17α-xxxxxxx-5α-xxxxxxxxx-3-xx)
•	7ß-xxxxxxx-XXXX		&xxxx;•	xxxxx-1-xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxx-5ɑ-xxxxxxx-1-xx-3-xx)
•	7-xxxx-XXXX		&xxxx;•	xxxxxxxxxxxxxx
•	11ß-xxxxx-19-xxxxxxxxxxxxxx		&xxxx;•	xxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4,9-xxxx-3-xx)
•	17ɑ-xxxxxxxxxxxxxxxxxxx (xxxxxxx)		&xxxx;•	xxxxxxxxxxxxxxxxxxx (17ß-hydroxy-17ɑ-metylestr-4-en-3-on)
•	19-norandrostenediol (xxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxxxxxxxx
•	19-xxxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxx (xxxxxxxxxxxxxx, 17ß-hydroxy-17ɑ-methylestra-4,9,11-trien-3-on)
•	Androst-4-en-3,11,17-trion(11-ketoandrostenedion, xxxxxxxxxxxx)		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxx (5ɑ-xxxxxxxxxxxxxxxxxx, 17ß-hydroxy-5ɑ-androstan-3-on)		•	nandrolon (19-xxxxxxxxxxxxxx)
•	xxxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxxxxxx (androst-4-en-3,17-dion)		•	norklostebol (4-xxxxxx-17β-xx-xxxx-4-xx-3-xx)
•	xxxxxxxxxx		&xxxx;•	xxxxxxxxxxxxx
•	xxxxxxxx		&xxxx;•	xxxxxxxx
•	xxxxxxx (androsta-1,4-dien-3,17-dion)		•	oxandrolon
•	calusteron		•	oxymesteron
•	klostebol		•	oxymetolon
•	danazol ([1,2]oxazolo[4’,5’:2,3]pregna-4-en- 20-xx-17ɑ-xx)		&xxxx;•	xxxxxxxxx (dehydroepiandrosteron, DHEA, 3β-xxxxxxxxxxxxxx-5-xx-17-xx)
•	xxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx- 17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxx-1,4-xxxx-3-xx)		&xxxx;•	xxxxxxxxxxx (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxx)
•	xxxxxxxxxxxxxxxxxxxxxx (17ɑ-xxxxxx-5ɑ-xxxxxxx-2-xx-17ß-xx x 17ɑ-xxxxx-5ɑ- xxxxxxx-3-xx-17ß- xx)		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxx (7ɑ,11ß-xxxxxxx-19-xxxxxxxxxxxxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxxx		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxxx (3β-xxxxxxx-5α-xxxxxxxxx-17-xx)		&xxxx;•	xxxxxxxxxxx
•	xxx-xxxxxxxxxxxxxxxxxx (17β-xxxxxxx-5β-xxxxxxxxx-3-xx)		&xxxx;•	xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18x-xxxx-19-xxx-17ɑ-xxxxxx-4,9,11-xxxxx-3-xx)
•	xxxxxxxxxxxxxx		&xxxx;•	xxxxxxx
•	xxxxxxxxxxxx (19-norpregna-4-en-17α-ol)		•	trenbolon (17β-xxxxxxxxxxx-4,9,11-xxxxx-3-xx)
•	xxxxxxxxxxxxxx		&xxxx;•	xxxxxxxxx (7ɑ-xxxxx-19-xxxxxxxxxxxxxx, XXXX)

x další xxxxx s podobnou xxxxxxxxx strukturou xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

X1.2. XXXXXXX XXXXXXXXXX XXXXX

Xxxx xxxx včetně:

Clenbuterol, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx modulátory xxxxxxxxxxxxx receptorů [SARM, xxxx. andarin, enobosarm (xxxxxxx), XXX-4033 (ligandrol), XXX140, X-23 x XX-11], zeranol a xxxxxxxxxx.

X2 XXXXXXXXX HORMONY, XXXXXXX XXXXXXX, PŘÍBUZNÉ XXXXX X MIMETIKA

ZAKÁZANÉ XXXXX (XXX SOUTĚŽI X XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx jsou Xxxxxxxxxxxx xxxxx.

Xxxxxxxxxxx xxxxx x xxxxx xxxxx x xxxxxxxx chemickou xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx xxxx xxxxxxxx.

X2.1. XXXXXXXXXXXXX (XXX) X XXXXX OVLIVŇUJÍCÍ XXXXXXXXXXX

Xxxx xxxx xxxxxx:

X2.1.1 Xxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxx, xxxx. darbepoetiny (xXXX); xxxxxxxxxxxxx (XXX); sloučeniny xxxxxxxx xx EPO, [xxxx. EPO-Fc, xxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX)]; EPO- xxxxxxxxx xxxxxxxxxx a xxxxxx sloučeniny, xxxx. XXXX-530, peginesatid.

S2.1.2 Aktivační xxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx (HIF), např. xxxxxx; xxxxxxxxxxx (GSK1278863); XXX2; xxxxxxxxxx (XXX 85-3934); xxxxxxxxxx (XX-4592); xxxxxxxxxx (XXX-6548); xenon.

S2.1.3 Xxxxxxxxxx GATA, např. X-11706.

X2.1.4 Xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxxxxxx růstového faktoru xxxx (TGF-β), xxxx. xxxxxxxxxxxx; xxxxxxxxxxx.

X2.1.5 Agonisté xxxxxxxxx xxxxxxxxx xxxxxxxxx, xxxx. xxxxxx EPO; xxxxxxxxxxxxx XXX (CEPO).

S2.2. XXXXXXXXX XXXXXXX X XXXXXX XXXXXXXXXX FAKTORY

S2.2.1 Xxxxxxx stimulující testosteron x xxxx, xxxx xxxx xxxxxx:

• choriový xxxxxxxxxxxx (XX),

• xxxxxxxxxxxx xxxxxx (XX),

• hormon xxxxxxxxxx gonadotropin (XxXX, xxxxxxxxxxx) a xxxx xxxxxxxxxxx xxxxxxx (např. xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx x xxxxxxxxxxx),

&xxxx;• kisspeptin x xxxx agonistické xxxxxxx.

X2.2.2 Xxxxxxxxxxxxxx a xxxxxx xxxxxxxxxx xxxxxxx, xxxx. xxxxxxxxxxxx x xxxxxxxxxxxxx.

X2.2.3 Xxxxxxx xxxxxx (XX), xxxx xxxxxxx x xxxxxxxxx, mimo xxxx xxxxxx:

• xxxxxxx xxxxxxxxx xxxxxxx, např. xxxxxxxxxxxxxxxxx, xxxxxxxxxxx x xxxxxxxxxx,

• xxxxxxxxx růstového xxxxxxx, např. XXX-9604 x hGH 176–191.

S2.2.4 Xxxxxxx xxxxxxxxxx růstový xxxxxx, mimo xxxx xxxxxx:

• xxxxxx xxxxxxxxxx xxxxxxx xxxxxx (GHRH) x xxxx analogy, xxxx. CJC-1293, XXX-1295, xxxxxxxxxx x tesamorelin,

• xxxxxxxxxxx xxxxxxxxx xxxxxxx (XXX) x xxxxxx xxxxxxxx [např. xxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx (XX-677), xxxxxxxxxx, xxxxxxxxxxx (xxxxxxx), xxxxxxxxxxx x tabimorelin],

• xxxxxxx xxxxxxxxxx XX (XXXX) [xxxx. xxxxxxxxxxxx, xxxxxxxxxx (xxxxxxxxx), XXXX-1, XXXX-2 (pralmorelin), XXXX-3, XXXX-4, XXXX-5 x XXXX-6].

X2.3. XXXXXXX XXXXXXX X XXXXXXXXXX RŮSTOVÝCH XXXXXXX

Xxxx jiné xxxxxx:

• xxxxxxxxxxxxx xxxxxxx faktory (XXX)

• hepatocytový xxxxxxx xxxxxx (HGF)

• růstový xxxxxx 1 podobný xxxxxxxx (XXX-1, mecasermin) x jeho analogy

• xxxxxxxxxx růstové xxxxxxx (XXX)

• xxxxxxx faktor xxxxxxxx x xxxxxxxx xxxxxxxx (PDGF)

• thymosin-β4 x jeho deriváty, xxxx. XX-500

• vaskulárně-endoteliární xxxxxxx xxxxxx (XXXX)

x xxxxx xxxxxxx xxxxxxx xxxx modulátory růstových xxxxxxx xxxxxxxxxxx xxxxxxx/xxxxxxxxx xxxxxxxx xx xxxxxxx, xxxxxxxx xxxx xxxxxx, xxxxxxxxxxxxx, xxxxxxx energie, xxxxxxxxxxxxx kapacitu nebo xxxxxxxxxxx xxxx xxxxxxxxx xxxxxx.

X3 XXXX-2 AGONISTÉ

ZAKÁZANÉ XXXXX (PŘI SOUTĚŽI X MIMO XXXXXX)

Xxxxxxx xxxxxxxx xxxxx v xxxx třídě xxxx Xxxxxxxxxx xxxxx.

Xxxxxxx xxxxxxxxxx x xxxxxxxxxxxx beta-2 xxxxxxxx xxxxxx všech xxxxxxxxx izomerů xxxx xxxxxxxx.

Xxxx jiné xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx (xxxxxxxxxxxxx)
•	xxxxxxxxx		•	xxxxxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx

XXXXXXX

• Xxxxxxxxx salbutamol: xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx x xxxxxxxxxx xxxxxxx, xxxxxxxxxxxxxxxx 600 xxxxxxxxxx xxxxx 8 xxxxx xx jakékoliv xxxxx;

• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx xxxxxx xxxxx 54 xxxxxxxxxx za 24 xxxxx;

• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 200 xxxxxxxxxx xx 24 xxxxx;

• xxxxxxxxx vilanterol: maximálně 25 xxxxxxxxxx xx 24 xxxxx.

XXXXXXXX

Xxxxxxxxxx salbutamolu x xxxx v xxxxxxxx xxxxxx xxx 1000 xx/xx nebo xxxxxxxxxxx v xxxxxxxx xxxxxx xxx 40 xx/xx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx xxxxx a xxxx považována za Xxxxxxxxx laboratorní nález (XXX), xxxxx Xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, že abnormální xxxxxxxx xxx xxxxxxxxx xxxxxxxxxxxx xxxxx (inhalační) xx do xxxx xxxxxxx xxxxxxxxx dávky.

S4 XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX

XXXXXXXX XXXXX (PŘI XXXXXXX X XXXX XXXXXX)

Xxxxxxxx látky ve xxxxxxx X4.1 x X4.2 xxxx Specifické xxxxx.

Xxxxx zařazené xx xxxx S4.3 x X4.4 xxxx Xxxxxxxxxxxx xxxxx.

Xxxxxxxxxxx xxxxxxxxx x xxxxxxxxxxx xxxxxxxxxx xxxx xxxxxxxx.

X4.1. INHIBITORY AROMATÁZ

Mimo xxxx xxxxxx:

•	2-xxxxxxxxxxx (5ɑ-xxxxxxx-2-xx-17-xx)		•	xxxxxxxx-1,4,6-xxxxx-3,17-xxxx (xxxxxxxxxxxxxxxxx)
•	2-xxxxxxxxxxx (5ɑ-androst-2-en-17-on)		•	androsta-3,5-dien-7,17-dion (xxxxxxxxx)
•	3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx)		•	xxxxxxxxx
•	3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx)		•	xxxxxxxxx
•	4-xxxxxxxxx-3,6,17 xxxxx (6-xxx)		•	xxxxxxxx
•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx

X4.2. XXXXXXXXXXXXXX XXXXX [XXXXXXXXXXXXX X XXXXXXXXXX XXXXXXXXXX ESTROGENOVÝCH XXXXXXXXX (XXXXX)]

Xxxx xxxx xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx (xxxxxxxxxxxxx)
•	xxxxxxxxx		•	xxxxxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx

X4.3. XXXXX XXXXXXXXXXX XXXXXXXX XXXXXXXXX XXXXXXXX XXX

Xxxx xxxx xxxxxx:

•	xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx A		•	inhibitory xxxxxxxxxx, např.:
•	konkurenty receptoru xxxxxxxx IIB, xxxx.:			- xxxxx xxxxxxxxx xxxx xxxxxx xxxxxxx xxxxxxxxxx
	- xxxxxxx receptory xxxxxxxx (xxxx. ACE-031)			- proteiny xxxxxx xxxxxxxxx (xxxx. xxxxxxxxxxx, xxxxxxxxx myostatinu)
•	protilátky xxxxx xxxxxxxxx xxxxxxxx XXX (xxxx. bimagrumab)			- xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx xxxx prekurzory (xxxx. xxxxxxxxxxx, xxxxxxx zumab, xxxxxxxxxxxxx, xxxxxxxxxx)

X4.4. XXXXXXXXXXX XXXXXXXXXX

X4.4.1 xxxxxxxxxx AMP-aktivované xxxxxxxxxxxxx (XXXX), např. XXXXX, xxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxx aktivovaného xxxxxxxxx xxxxx (XXXXδ), např. 2-(2-xxxxx-4-((4-xxxxx-2-(4- (xxxxxxxxxxxxx)xxxxx)xxxxxxx-5-xx)xxxxxxxxx)xxxxxx) xxxxxxxx xxxxxx (XX1516, GW501516) x xxxxxxxx Rev-erbɑ , xxxx. XX9009, XX9011

X4.4.2 xxxxxxxx x xxxxxxxx xxxxxxxx

X4.4.3 meldonium

S4.4.4 xxxxxxxxxxxx

X5 DIURETIKA A XXXXXXXXX XXXXX

XXXXXXXX XXXXX (XXX SOUTĚŽI X XXXX SOUTĚŽ)

Všechny zakázané xxxxx x xxxx xxxxx jsou Specifické xxxxx.

Xxxxxxx xxxxxxxxx x xxxxxxxxx látky, xxxxxx xxxxx xxxxxxxxx xxxxxxx, xxxx. x- a x-, jsou xxxxxxxx.

Xxxx xxxx včetně:

•  Xxxxxxxxx, xxxx xxxx.:

xxxxxxxxxxxx; amilorid; xxxxxxxxx; xxxxxxxx; xxxxxxxxxxxx; xxxxxxxx xxxxxxxxxx; xxxxxxxxx; xxxxxxxxx; metolazon; spironolakton; xxxxxxxx, xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx x xxxxxxxxxxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx;

• Xxxxxxx, xxxx. xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx;

• Xxxxxxxxxxx xxxxxxxxx xxxxxxxx intravenózně, např.:

albumin, xxxxxxx, hydroxyetyl škrob, xxxxxxxx;

• Xxxxxxxxxxx;

• Xxxxxxxxxx;

x xxxxx xxxxx s xxxxxxxx xxxxxxxxx strukturou xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

XXXXXXX

• xxxxxxxxxxx; xxxxxxxx; x xxxxxxx xxxxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxxxxxxxx (xxxx. xxxxxxxxxx, brinzolamid);

• xxxxxxx xxxxxx felypresinu x xxxxx xxxxxxxxx.

XXXXXXXX

Xxxxx xxxxxxxxxxx xxxxxxxx látky xx xxxxxxxxxx prahovým xxxxxxx: u xxxxxxxxxxx, xxxxxxxxxxx, xxxxxx, efedrinu, xxxxxxxxxxxxx x xxxxxxxxxxxxxx xx Xxxxxx Xxxxxxxxx xxxxxxxx xxxx xxxxxxxx Xxx Soutěži ve xxxxxxx x xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxxx (kromě xxxxxxxxx xxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx felypresinu v xxxxxxxx xxxxxxxxx), xxxx xxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx xxxxx (XXX), xxxxx Xxxxxxxxx nemá xxxxxxxxxx Xxxxxxxxxxxxx xxxxxxx (XX) xx xxxx xxxxx xxxxx x xx, xxxxx xxx xxxx udělena xx xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxx.

XXXXXXXX XXXXXX

XXXXXXXX XXXXX (PŘI SOUTĚŽI X XXXX SOUTĚŽ)

Všechny xxxxxxxx xxxxxx x xxxx xxxxx jsou Xxxxxxxxxxxx x výjimkou xxxxx x X2.2, xxx xxxx Xxxxxxxxxx xxxxxx.

X1. MANIPULACE S XXXX X KREVNÍMI XXXXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

X1.1. Xxxxxx nebo xxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxx, xxxxxxxxx (xxxxxxxxx) xxxx xxxxxxxxxxx xxxx xxxx xxxxxxxx x xxxxxxxxx krvinek xxxxxxxxxxx xxxxxx xx xxxxxxxxx xxxxxxx x xxxxxxxx xxxxxxxx xxxxxx nebo xxxxxx složek Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxx provedené x xxxxxxxxxxxxx xxxxxxxxx xxxxxx.

X1.2. Umělé zvyšování xxxxxx, xxxxxxx xxxx xxxxxxx xxxxxxx.

Xxxx xxxx xxxxxx:

Xxxxxxxxxxxxxxxxxxx; efaproxiral (XXX13); xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx, xxxx. xxxxxx xxxxxxxx xx xxxx xxxxxxxxxxx x xxxxxxxxxxxxxxxx hemoglobinové xxxxxxxx, x xxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxxx.

X1.3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx x xxxx xxxx x xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx nebo xxxxxxxxxx xxxxxxx.

X2. XXXXXXXX X XXXXXXXXX MANIPULACE

Zakázané je xxxxxxxxxxx:

X2.1. Xxxxxxxxx xxxx Xxxxx o xxxxxx xx xxxxxx xxxxxxx xxxxxxxxx x xxxxxxxx Xxxxxx xxxxxxxxxx xxx Xxxxxxxxx xxxxxxxx.

Xxxx xxxx xxxxxx:

Xxxxxx x/xxxx xxxxxx Xxxxxx, xxxx. xxxxxxxx xxxxxxx xx Xxxxxx.

X2.2. Xxxxxxxxxx xxxxxx x/xxxx xxxxxxx xxxx xxx xxxxxx 100 xx xx 12 hodin xxxxx xxxxxx xxxxxxxxx xxxxxxxxx x průběhu xxxxxxxxxxxx xxxxxxxx, xxxxxxxxxxxxx xxxxxxx nebo xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx.

X3. XXXXXX X XXXXXXX DOPING

Z xxxxxx xxxxxxxxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxx následující:

M3.1. Použití xxxxxxxxxx xxxxxxx xxxx xxxxxx xxxxxxx, xxxxx xxxxx xxxxxx xxxxxxxx xxxxxx x/xxxx xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxx. Xx xxxx xxxx xxxxxxxx technologie xxxxx xxxx, xxxxxxxxx xxxx x xxxxxxxxxxx xxxxxxx xxxx.

X3.2. Xxxxxxx xxxxxxxxxx xxxx geneticky xxxxxxxxxxxxxx xxxxx.

X6 XXXXXXXXXXX

XXXXXXXX XXX XXXXXXX

Xxxxxxx xxxxxxxx xxxxx x xxxx třídě xxxx Xxxxxxxxxx látky x výjimkou xxxxx xxxxxxxxx v S6.A, xxx jsou Xxxxxxxxxxxx xxxxx.

Xxxxxxxx látky v xxxx sekci: xxxxxx x metylendioxymetamfetamin (XXXX/„xxxxxx“)

Xxxxxxx xxxxxxxxxxx, xxxxxx xxxxx xxxxxxxxx xxxxxxx, např. x- a x-, xxxx xxxxxxxx.

Xxxxxxxxxxx xxxxxxxx:

X6.X: XXXXXXXXXXXX STIMULANCIA

•	adrafinil		•	fonturacetam [4-xxxxxxxxxxxxxx (xxxxxxxx)]
•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxx
•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxxx(x-)
•	xxxxxxxxx		•	x-xxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxx		•	xxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx
•	xxxxxxxxxxx

Xxxxxxxxx, xxxxx xxxx xxxxxxxx uveden x xxxxx xxxxxx, je Xxxxxxxxxxx xxxxxx.

X6.X: SPECIFICKÁ XXXXXXXXXXX

Xxxx xxxx včetně:

•	2-fenylpropan-1-amin (ß-xxxxxxxxxxxxxx-xxxx, XXXXX)		•	xxxxxxxxxxx		•	xxxxxxxxx
•	3-xxxxxxxxxx-2-xxxx (1,2-dimetylpentylamin)		•	fenbutrazát		•	oxilofrin (xxxxxxxxxxxxx)
•	4-xxxxxxxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxx
•	4-xxxxxxxxxx-2-xxxx (1,3-xxxxxxxxxxxxxxx, 1,3 XXXX, metylhexanamin)		•	heptaminol		•	pentetrazol
•	4-methylpentan-2-amin (1,3-xxxxxxxxxxxxxxxxx)		•	xxxxxxxxxx (xxxxxxxxx)		•	xxxxxxxxxxx x xxxx xxxxxxxx
•	5-xxxxxxxxxx-2-xxxx (1,4-xxxxxxxxxxxxxxx, 1,4-xxxxxxxxxxxxxxxxx, 1,4-XXXX)		•	xxxxxxxxxxxxxxxx (parahydroxyamfetamin)		•	fenmetrazin
•	benzfetamin		•	isomethepten		•	fenprometamin
•	katin1)		•	levmetamfetamin		•	propylhexedrin
•	katinon x xxxx xxxxxxx, xxxx. xxxxxxxx, metedron a ɑ-xxxxxxxxxxxxxxxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxxxxxx2)
•	xxxxxxxxxxxxxx (xxxxxxxxxxxxxxxx)		•	xxxxxxxxxxxxxxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxx3)		•	xxxxxxxxxxxx3)		•	xxxxxxxxxx
•	xxxxxxxxx (xxxxxxxxx)4)		•	xxxxxxxxxxxxx [(±)-xxxxx-2-(xxxxxxxx-2-xx)-2-(xxxxxxxxx-2- xx)xxxxxx]		•	xxxxxxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx)
•	xxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxx (1,5-xxxxxxxxxxxxxxxx)

x další xxxxx x podobnou xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx

XXXXXXX

• xxxxxxxx;

• xxxxxxxx xxxxxxxxxxx x xxxxxxx xxxxxx xxxxxxx, xxxxxxx, očního xxxx xxxxxx použití (xxxx. xxxxxxxxxx, klonazolin, xxxxxxxxxxx, xxxxxxxxxxx, nafazolin, oxymetazolin, xxxxxxxxxx, tramazolin, xxxxxxxxxxxxx) x xxxxxxxxxxx xxxxxxxx xx Xxxxxxxxxxxxxx programu 2024⁵⁾.

X7 XXXXXXXXX

XXXXXXXX XXX XXXXXXX

Xxxxxxx xxxxxxxx xxxxx x této třídě xxxx Specifické xxxxx.

Xxxxxxxx xxxxx x xxxx xxxxx: diamorfin (xxxxxx)

Xxxxxxxxxxx xxxxxxxxx, xxxxxx xxxxxx xxxxxxxxxx všech xxxxxxxxx xxxxxxx, xxxx. x- x x, xxxx xxxxxxxx.

•	xxxxxxxxxxx		•	xxxxxxxx x xxxx xxxxxxxx		•	xxxxxx		•	xxxxxxxxxx
•	xxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxx
•	xxxxxxxxx (xxxxxx)		•	xxxxxxx		•	xxxxxxxx		•	xxxxxxxx
						•	xxxxxxxxx

X8 XXXXXXXXXXX

XXXXXXXX XXX SOUTĚŽI

Všechny xxxxxxxx xxxxx x xxxx xxxxx jsou Xxxxxxxxxx xxxxx. Xxxxxxxx xxxxx x této sekci: xxxxxxxxxxxxxxxxxxx (XXX)

Xxxxxxx xxxxxxxx x xxxxxxxxxx kanabinoidy xxxx zakázané, např.

• x xxxxxx (hašiš, xxxxxxxxx) x xxxxxxxxx xxxxxxxxxx

• přírodní x xxxxxxxxxx tetrahydrokanabionoly (XXX)

• xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxx xxxxxx THC

VÝJIMKY

• kanabidiol

S9 XXXXXXXXXXXXXXX

XXXXXXXX PŘI XXXXXXX

Xxxxxxx xxxxxxxx xxxxx x xxxx třídě xxxx Xxxxxxxxxx látky.

Všechny glukokortikoidy xxxx zakázány, xxxxx xxxx xxxxxxxx xxxxxxxxxx xxxxxxxx, xxxxxxxxx [xxxxxx xxxxxxxxxx (xxxx. xxxxxxx, xxxxxxxxxx, sublingvální)] nebo xxxxxxxx cestou.

Mimo xxxx xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxxx xxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxxxxxx

XXXXXXXX

• Xxxx xxxxxxx xxxxxx (xxxxxx xxxxxxxxxxx a xxxxxxxxx: xxxxxxxx-xxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxxxxxxx, xxxxxx x xxxxxxxxxxxx) xxxxxx xxxxxxxx, xxxxx se xxxxxxxxx x xxxxx xxxxxxxx xxxxxxxxxxxx xxxxx a xxxxxxxxxxxxxx xxxxxxxx.

X1 XXXX-XXXXXXXXX

XXXXXXXX X URČITÝCH SPORTECH

Všechny xxxxxxxx xxxxx x xxxx xxxxx jsou Xxxxxxxxxx xxxxx.

Xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx x xxxxxxxxxxxxx sportech Xxx Xxxxxxx x kde xx xx xxxxxxxx xxxxxxxx (*) i Xxxx xxxxxx.

• xxxxxxxxxxx (XX)*

• xxxxxxxx/xxxxxxxxxxxx (XXX) – skoky xx xxxxxx, xxxxxxxxxxx xxxxx / U-rampa x xxxxxxxxx X-xxxxx / xxx xxx

• automobilový xxxxx (XXX)

• podvodní xxxxxx (CMAS)* x xxxxxxxxxxxx xxxxxxx xxxxxxxx, xxxx xxxxxxxx a xxxxxxx xx xxxx

• xxxxxxxx (xxxxxxx xxxxxxxxxx) (XXXX)

• šipky (XXX)

• xxxx (XXX)

• xxxxxxxx (XXX)

• xxxxxxx (XXXX, XXX)*

* xxxxxxxx také Xxxx xxxxxx

Xxxx xxxx xxxxxx:

•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxx
•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxxxx		•	xxxxxxx

Xxxxxxx x. 2

Xxxxx xxxxxxxxxxx smlouvy x xxxxxxxxx xxxxxx
&xxxx;

¹⁾ xxxxx (x-xxxxxxxxxxxxxxxx) x xxxx x-xxxxxx: je zakázaný xxxxx xxx xxxxxxxxxxx x xxxx xxxxx xxx 5 mikrogramů x 1 ml.

²⁾ xxxxxxxxxxxxx: zakázaný xxxxx xxx xxxxxxxxxxx x xxxx vyšší xxx 150 xxxxxxxxxx v 1 xx.

³⁾ efedrin x xxxxxxxxxxxx: zakázány xxx xxxxxxxxxxx x xxxx vyšší xxx 10 xxxxxxxxxx x 1 xx.

⁴⁾ xxxxxxxxx (xxxxxxxxx): xxxx xxxxxxxx xxxxxxx podávání, např. xxxxx, oční, xxxx xxxxxxxx xxxxxxxx s xxxxxxxxx xxxxxxxxxx.

⁵⁾ xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, xxxxxxxxx x xxxxxxxx: xxxx xxxxx xxxx xxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx 2024 x nejsou xxxxxxxxxx xx Zakázané xxxxx.

Xxxxxxxxx

Xxxxxx xxxxxxx x. 19/2025 Xx. xxxxx xxxxxxxxx xxxx 28.1.2024.

Xxxxx xxxxxxxxxxxx xxxxxxxx norem xxxxxx právních xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx xx xxxx xxxxxx xxxxxxxxx xxxxx xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx